...
首页> 外文期刊>Medical hypotheses >Regulation of the inducible nitric oxide synthase and sodium pump in type 1 diabetes.
【24h】

Regulation of the inducible nitric oxide synthase and sodium pump in type 1 diabetes.

机译:1型糖尿病诱导型一氧化氮合酶和钠泵的调节。

获取原文
获取原文并翻译 | 示例
           

摘要

Insulin-like growth factor-1 (IGF-1) is a hormone and growth factor closely related to insulin. The autocrine/paracrine actions of IGF-1 involve activation of inducible nitric oxide synthase (iNOS) and the Na(+), K(+)-ATPase sodium pump in cardiovascular tissues. Data from literature indicate that iNOS is expressed in vascular smooth muscle cells (VSMC) and that IGF-1-induced release of NO is both rapid and delayed. We hypothesize that impaired IGF-1-induced sodium pump activity/expression in rats with type 1 diabetes is related to activation of phosphatidylinositol 3 kinase (PI3K)/cytosolic phospholipase 2 (cPLA(2))/protein kinase B (Akt) signaling, and that IGF-1 prevents acute and chronic dysfunction of iNOS and sodium pump activity in a chemically induced model of type 1 diabetes, the streptozotocin-treated rat heart (STZ). Understanding how iNOS and sodium pump activity are regulated by IGF-1 activation of the PI3K/cPLA(2)/Akt cascade should provide novel and fundamental knowledge regarding the regulatory actions of IGF-1 in promoting vasodilation. Since insulin resistance is currently a major focus of research, the use of IGF-1 to improve insulin resistance and glucose metabolism has opened a new arena for treatment of comorbid conditions. Future investigations should now focus on mechanisms of action of IGF-1 and its clinical applicability.
机译:胰岛素样生长因子-1(IGF-1)是与胰岛素密切相关的激素和生长因子。 IGF-1的自分泌/旁分泌作用涉及心血管组织中诱导型一氧化氮合酶(iNOS)和Na(+),K(+)-ATPase钠泵的激活。来自文献的数据表明,iNOS在血管平滑肌细胞(VSMC)中表达,而IGF-1诱导的NO释放既迅速又延迟。我们假设1型糖尿病大鼠中IGF-1诱导的钠泵活性/表达受损与磷脂酰肌醇3激酶(PI3K)/胞质磷脂酶2(cPLA(2))/蛋白激酶B(Akt)信号传导有关,在化学诱导的1型糖尿病模型(链脲佐菌素治疗的大鼠心脏(STZ))中,IGF-1可以预防iNOS的急性和慢性功能障碍以及钠泵活动。了解如何通过PI3K / cPLA(2)/ Akt级联的IGF-1激活来调节iNOS和钠泵的活性,应提供有关IGF-1在促进血管舒张中的调控作用的新颖和基础知识。由于胰岛素抵抗目前是研究的主要重点,因此使用IGF-1改善胰岛素抵抗和葡萄糖代谢为治疗合并症开辟了新领域。现在,未来的研究应集中在IGF-1的作用机理及其临床适用性上。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号